drugset
drugset / Trial / NCT06323369

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

NCT06323369 ↗

Phase 2 Recruiting 154 enrolled Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RandomizedParallel-groupOpen-labelPrevention

Summary

A prospective, randomized, open-label, multicenter Phase 2 trial designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable clinically node-negative head and neck squamous cell carcinoma.

Timeline

Start
2024-03-25
Primary completion
2029-03-25
Completion
2029-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 260 mg/m2 Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma